We have identified a novel structural class of protein serine/threonine kinase inhibitors
comprised of an aminoimidazo [1, 2-a] pyridine nucleus. Compounds from this family are …

The protein kinase family represents an enormous opportunity for drug development.
However, the current limitation in structural diversity of kinase inhibitors has complicated …

Structure-based design approach was successfully used to guide the evolution of
imidazopyridine scaffold yielding new structural class of highly selective inhibitors of cyclin …

High-throughput screening identified the imidazo [1, 2-a] pyridine and bisanilinopyrimidine
series as inhibitors of the cyclin-dependent kinase CDK4. Comparison of their …

A piperazine series of cyclin-dependent kinase (CDK) inhibitors have been identified. The
compounds exhibit excellent physiochemical properties and a novel binding mode, whereby …

Exploration of SAR and optimisation of the imidazo [1, 2-a] pyridine CDK inhibitors has lead
to the discovery of novel, potent and selective inhibitors of the cyclin-dependent kinase …

Modification of imidazo [1, 2-a] pyridine CDK inhibitors lead to identification of less lipophilic
imidazo [1, 2-b] pyridazine series of CDK inhibitors. Although several equivalent compounds …

A series of aminobenzimidazole-substituted pyrimidines were synthesized and evaluated for
biochemical activity against CDK1. A high-speed parallel synthesis approach enabled the …

The development of a novel series of imidazole pyrimidine amides as cyclin-dependent
kinase (CDK) inhibitors is described. The series was found to have much improved CDK2 …

An imidazole series of cyclin-dependent kinase (CDK) inhibitors has been developed.
Protein inhibitor structure determination has provided an understanding of the emerging …